| Expression pattern: |
UP |
| Associated gene: |
ACTG1 |
| Associated microRNA: |
miR-485-5p |
| Biological function: |
promotes CRC proliferation, EMT, glycolysis, tumor growth, and TAM M2 polarization; inhibits apoptosis and TAM M1 markers |
| Molecular mechanism: |
ceRNA mechanism: circPLCE1 competitively binds miR-485-5p to mediate ACTG1 |
| Biological pathway or process: |
EMT (promotes); glycolysis (promotes); proliferation (promotes); apoptosis (inhibits); macrophage polarization (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Clinical Sample Validation; Bioinformatics Analysis; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); Transfection; Colony Formation Assay; Annexin V/PI Flow Cytometry; Flow Cytometry（Non-apoptosis/cycle）; Western Blot; In Vivo Animal Model; IHC (Immunohistochemistry) |
| Clinical significance: |
circPLCE1 was relevant to lymph node metastasis in CRC patients; speculated as a biomarker for diagnosis and prognosis |
| Description: |
circPLCE1 is up-regulated in colorectal cancer and promotes tumor growth, EMT and glycolysis, while driving tumor-associated macrophage polarization toward the M2 phenotype. Mechanistically, it functions as a ceRNA by sponging miR-485-5p to increase ACTG1, forming a circPLCE1/miR-485-5p/ACTG1 axis. |
| Confidence score: |
0.7548 |